Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Adipose tissue (AT) has recently been identified as a dynamic endocrine organ secreting a wide range of adipokines. Adiponectin is one such hormone, exerting endocrine and paracrine effects on the cardiovascular system. At a cellular and molecular level, adiponectin has anti‐inflammatory, antioxidant and anti‐apoptotic roles, thereby mitigating key mechanisms underlying cardiovascular disease (CVD) pathogenesis. However, adiponectin expression in human AT as well as its circulating levels are increased in advanced CVD states, and it is actually considered by many as a ‘rescue hormone’. Due to the complex mechanisms regulating adiponectin's biosynthesis in the human AT, measurement of its levels as a biomarker in CVD is highly controversial, given that adiponectin exerts protective effects on the cardiovascular system but at the same time its increased levels flag advanced CVD. In this review article, we present the involvement of adiponectin in CVD pathogenesis and we discuss its role as a clinical biomarker. Linked Articles: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Reactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625 · cited 2×
“It has been increasingly recognized that adipose tissue (AT) is not merely an energy storage depot, but rather a dynamic endocrine organ, secreting numerous adipokines with widereaching effects on human homeostasis (Ouchi et al., 2011).”
BackgroundSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961 · cited 2×
“Although subcutaneous and visceral WAT are both able to produce adiponectin to a significant extent, the expression of adiponectin in visceral AT may be of greater clinical significance, because it displays striking variations under certain pathophysiological states such as obesity (Wajchenberg, 2000).”
BackgroundAdiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Kadowaki, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29126 · Cited by 2,824 · cited 3×
“Adiponectin is secreted almost exclusively from AT (Scherer et al., 1995), and its circulating levels are reduced in obesity and insulin resistance (Kadowaki et al., 2006).”
BackgroundAdiponectin and Adiponectin Receptors
Kadowaki, T., & Yamauchi, T. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0005 · Cited by 2,634
Subcutaneous and visceral adipose tissue: Structural and functional differences
Ibrahim, M. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00623.x · Cited by 2,238
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
Rotter, V., Nagaev, I., & Smith, U. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301977200 · Cited by 1,062 · cited 1×
“…(Mittal et al., 2014) Pro-atherogenic (Battes et al., 2014) Positive association with CVD risk (Ridker et al., 2000) IL-6 Induces IR (Rotter et al., 2003) Pro-inflammatory (Libby et al., 2002) Pro-oxidant (Mittal et al., 2014) Pro-atherogenic (Huber et al., 1999) Positive…”
BackgroundSphingosine-1-phosphate signaling and its role in disease
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.003 · Cited by 1,039 · cited 2×
“Stimulation of ceramidase activity has multiple beneficial metabolic and insulin-sensitizing effects, whereas S1P itself is a diverse second messenger with reportedly anti-inflammatory and anti-apoptotic functions (Maceyka et al., 2012).”
BackgroundRidker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.18.2149 · Cited by 934
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892 · cited 9×
“, 2015), and the potential ability of adiponectin to regulate this parameter may be of crucial importance in the regulation of cardiovascular responses to a variety of stressful and pathogenic stimuli (Holland et al., 2011).”
BackgroundInfluentialA small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757 · cited 1×
“A recent study identified an orally active small molecule named AdipoRon, which binds to Adipo1 and Adipo2 receptors, activating PPARγ and AMPK pathways (Okada-Iwabu et al., 2013).”
BackgroundAdiponectin-mediated modulation of hypertrophic signals in the heart
Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D. R., Kumada, M., Sato, K., Schiekofer, S., Ohashi, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1137 · Cited by 671 · cited 1×
“Adiponectin-deficient mice have enhanced concentric cardiac hypertrophy and increasedmortality in response to pressure overload and angiotensin II infusion compared with wild-type mice, which were reversed following adiponectin supplementation (Shibata et al., 2004).”
BackgroundAdiponectin Promotes Macrophage Polarization toward an Anti-inflammatory Phenotype
Ohashi, K., Parker, J. L., Ouchi, N., Higuchi, A., Vita, J. A., Gokce, N., Pedersen, A. A., Kalthoff, C., Tullin, S., Sams, A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088708 · Cited by 646 · cited 2×
“, 2005); accordingly, macrophages from adiponectin-deficient mice display increased expression of inflammatory M1-type markers and reduced anti-inflammatory M2-type markers (Ohashi et al., 2010).”
BackgroundLocal and systemic effects of the multifaceted epicardial adipose tissue depot
Iacobellis, G. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.58 · Cited by 605
Tsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M., Suzuki, R., Hara, K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402367200 · Cited by 550
Oxidative stress and diabetic cardiovascular complications
Jay, D., Hitomi, H., & Griendling, K. K. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.06.018 · Cited by 464
Adiponectin signaling and function in insulin target tissues
Ruan, H., & Dong, L. Q. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw014 · Cited by 395 · cited 4×
“Increased visceral AT Table 1 Established adipocytokines and their biological roles Adipokine Biological roles IR Inflammation Oxidative stress Atherogenesis CVD risk Adiponectin Insulin-sensitising (Ruan and Dong, 2016) Anti-inflammatory (Turer and Scherer, 2012) Antioxidant (Margaritis et al., 2013; Antonopoulos et…”
BackgroundInfluentialAdiponectin and Future Coronary Heart Disease Events Among Men With Type 2 Diabetes
Schulze, M. B., Shai, I., Rimm, E. B., Li, T., Rifai, N., & Hu, F. B. (2005) · Diabetes · doi:10.2337/diabetes.54.2.534 · Cited by 365 · cited 6×
“Several drug classes used in the treatment of T2DM and in CVD have been found to increase circulating adiponectin levels.”
BackgroundInfluentialAdiponectin and Coronary Heart Disease: The Strong Heart Study
Lindsay, R. S., Resnick, H. E., Zhu, J., Tun, M. L., Howard, B. V., Zhang, Y., Yeh, J., & Best, L. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000153090.21990.8c · Cited by 169 · cited 1×
“However, the association between low adiponectin levels and the development of CAD has failed to be shown in several prospective studies (Lawlor et al., 2005; Lindsay et al., 2005).”
BackgroundYan, W., Zhang, H., Liu, P., Wang, H., Liu, J., Gao, C., Liu, Y., Lian, K., Yang, L., Sun, L., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0329-1 · Cited by 169
Antoniades, C., Shirodaria, C., Crabtree, M., Rinze, R., Alp, N., Cunnington, C., Diesch, J., Tousoulis, D., Stefanadis, C., Leeson, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.704155 · Cited by 153
Self-citationAdipocytes and adipose tissue.
Kiess, W., Petzold, S., Töpfer, M., Garten, A., Blüher, S., Kapellen, T., Körner, A., & Kratzsch, J. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.10.002 · Cited by 130 · cited 2×
“BAT contains much smaller lipid droplets and a larger amount of blood vessels, hence its darker, macroscopically brown appearance (Kiess et al., 2008).”
BackgroundHao, G., Li, W., Guo, R., Yang, J.-G., Wang, Y., Tian, Y., Liu, M.-Y., Peng, Y.-G., & Wang, Z.-W. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.02.018 · Cited by 82 · cited 2×
“Contrary to expectation, these studies associated higher circulating adiponectin levels with increased CVD risk and total mortality (Sook Lee et al., 2013), and with higher risk of stroke (Hao et al., 2013).”
ResultPerspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity
Okada-Iwabu, M., Iwabu, M., Ueki, K., Yamauchi, T., & Kadowaki, T. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.363 · Cited by 60 · cited 1×
“In the hope of optimizing the agonist, the group went on to establish the crystal structure of the adiponectin receptors using X-ray crystallography (Okada-Iwabu et al., 2015).”
Background
Cited by
Obesity and the risk of cardiometabolic diseases
Valenzuela, P. L., Carrera-Bastos, P., Castillo-García, A., Lieberman, D. E., Santos-Lozano, A., & Lucia, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00847-5 · Cited by 452
Perivascular adipose tissue inflammation in vascular disease
Nosalski, R., & Guzik, T. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13705 · Cited by 398
Adiponectin: Structure, Physiological Functions, Role in Diseases, and Effects of Nutrition
Khoramipour, K., Chamari, K., Hekmatikar, A. A., Ziyaiyan, A., Taherkhani, S., Elguindy, N. M., & Bragazzi, N. L. (2021) · Nutrients · doi:10.3390/nu13041180 · Cited by 336
Mohorko, N., Černelič-Bizjak, M., Poklar-Vatovec, T., Grom, G., Kenig, S., Petelin, A., & Jenko-Pražnikar, Z. (2019) · Nutrition Research · doi:10.1016/j.nutres.2018.11.007 · Cited by 147
Liu, Y., Vu, V., & Sweeney, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00842 · Cited by 69
Metadata
- Authors
- Woodward, L., Akoumianakis, I., & Antoniades, C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-10-19
- Volume
- 174
- Issue
- 22
- Pages
- 4007-4020
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2521306464
- Cited by
- 146
- References
- 28
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.